Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker NMRA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Anup Arora | 5.79M | 3.1% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Parag Shah | 5.79M | 3.1% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | K2 HealthVentures Equity Trust LLC | 5.79M | 3.1% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Raymond Debbane | 8.50M | 4.7% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Ulys, L.L.C. | 757,792 | 0.4% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Avicenna Life Sci Master GP LLC | 757,792 | 0.4% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Avicenna Life Sci Master Fund LP | 757,792 | 0.4% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Siren, L.L.C. | 7.74M | 4.3% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Invus Global Management, LLC | 7.74M | 4.3% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Invus Public Equities Advisors, LLC | 7.74M | 4.3% | SCHEDULE 13G/A ↗ |
| May 4, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Invus Public Equities, L.P. | 7.74M | 4.3% | SCHEDULE 13G/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | Steven Gillis | 31.53M | 17.3% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | Kristina Burow | 33.97M | 18.7% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | Clinton Bybee | 3.71M | 2.0% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | Keith Crandell | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | Robert Nelsen | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners XII, LLC | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners X, LLC | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners VIII, LLC | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners VII, LLC | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners XII, L.P. | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners X Overage, L.P. | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners X, L.P. | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners VII, L.P. | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Fund XII, L.P. | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Fund X Overage, L.P. | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Fund X, L.P. | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Fund VIII Overage, L.P. | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Apr 1, 2026 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Fund VII, L.P. | 33.85M | 18.6% | SCHEDULE 13D/A ↗ |
| Feb 19, 2026 | SCHEDULE 13G | NMRA Neumora Therapeutics, Inc. | Raymond Debbane | 9.00M | 5.4% | SCHEDULE 13G ↗ |
| Feb 19, 2026 | SCHEDULE 13G | NMRA Neumora Therapeutics, Inc. | Ulys, L.L.C. | 825,008 | 0.5% | SCHEDULE 13G ↗ |
| Feb 19, 2026 | SCHEDULE 13G | NMRA Neumora Therapeutics, Inc. | Avicenna Life Sci Master GP LLC | 825,008 | 0.5% | SCHEDULE 13G ↗ |
| Feb 19, 2026 | SCHEDULE 13G | NMRA Neumora Therapeutics, Inc. | Avicenna Life Sci Master Fund LP | 825,008 | 0.5% | SCHEDULE 13G ↗ |
| Feb 19, 2026 | SCHEDULE 13G | NMRA Neumora Therapeutics, Inc. | Siren, L.L.C. | 8.17M | 4.9% | SCHEDULE 13G ↗ |
| Feb 19, 2026 | SCHEDULE 13G | NMRA Neumora Therapeutics, Inc. | Invus Global Management, LLC | 8.17M | 4.9% | SCHEDULE 13G ↗ |
| Feb 19, 2026 | SCHEDULE 13G | NMRA Neumora Therapeutics, Inc. | Invus Public Equities Advisors, LLC | 8.17M | 4.9% | SCHEDULE 13G ↗ |
| Feb 19, 2026 | SCHEDULE 13G | NMRA Neumora Therapeutics, Inc. | Invus Public Equities, L.P. | 8.17M | 4.9% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Anup Arora | 9.00M | 5.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | Parag Shah | 9.00M | 5.0% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | NMRA Neumora Therapeutics, Inc. | K2 HealthVentures Equity Trust LLC | 9.00M | 5.0% | SCHEDULE 13G/A ↗ |
| Oct 29, 2025 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | Steven Gillis | 31.53M | 19.2% | SCHEDULE 13D/A ↗ |
| Oct 29, 2025 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | Kristina Burow | 33.96M | 20.7% | SCHEDULE 13D/A ↗ |
| Oct 29, 2025 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | Clinton Bybee | 3.71M | 2.3% | SCHEDULE 13D/A ↗ |
| Oct 29, 2025 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | Keith Crandell | 33.85M | 20.6% | SCHEDULE 13D/A ↗ |
| Oct 29, 2025 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | Robert Nelsen | 33.85M | 20.6% | SCHEDULE 13D/A ↗ |
| Oct 29, 2025 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners XII, LLC | 33.85M | 20.6% | SCHEDULE 13D/A ↗ |
| Oct 29, 2025 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners X, LLC | 33.85M | 20.6% | SCHEDULE 13D/A ↗ |
| Oct 29, 2025 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners VIII, LLC | 33.85M | 20.6% | SCHEDULE 13D/A ↗ |
| Oct 29, 2025 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners VII, LLC | 33.85M | 20.6% | SCHEDULE 13D/A ↗ |
| Oct 29, 2025 | SCHEDULE 13D/A (amended) | NMRA Neumora Therapeutics, Inc. | ARCH Venture Partners XII, L.P. | 33.85M | 20.6% | SCHEDULE 13D/A ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 8:14 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances